Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$11.61
52-Week Range
Decision Context
Altman Z-Score indicates financial distress risk. Review debt levels and cash runway before any position sizing decision.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.64%
Accommodative
10-Year Treasury
4.32%
2026-04-01
Unemployment
4.3%
Near full employment
CPI Index
332.4
2026-04-01
M2 Money Supply
$22.8T
2026-04-01
The Federal Funds rate stands at 3.64% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.32%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.3%; Industrial production index is at 102.5; M2 money supply is $22.8T; CPI index stands at 332.4.
SWOT Analysis — PRGO
Inflationary BoomStrengths
No standout strengths identified from the filing.
Weaknesses
Net Income: -$1.4B (-729.7% YoY) — The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted): $-10.29 (-723.2% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
Operating Cash Flow: $238.5M (-34.3% YoY) — Operating cash flow fell 34% but remained positive.
Total Assets: $8.5B (-11.5% YoY) — Total assets shrank 12% — the balance sheet contracted.
Gross Profit: $1.5B (-3.1% YoY) — Gross profit declined 3% — costs are growing faster than revenue.
R&D spending is 11925% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
Net loss of $1.4B — the company spent more than it earned. Investors should monitor the path to profitability.
Financial Charts
Revenue vs Net Income
Gross Profit vs Operating Income
Operating Cash Flow
Year-over-Year Changes
Net Income
-$1.4B
was -$171.8M
The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted)
$-10.29
was $-1.25
Negative EPS — the company recorded a loss on a per-share basis.
Operating Cash Flow
$238.5M
was $362.9M
Operating cash flow fell 34% but remained positive.
Total Assets
$8.5B
was $9.6B
Total assets shrank 12% — the balance sheet contracted.
Gross Profit
$1.5B
was $1.5B
Gross profit declined 3% — costs are growing faster than revenue.
Risk Flags
1 high · 0 medium · 1 low- ⚠ High
Net loss of $1.4B — the company spent more than it earned. Investors should monitor the path to profitability.
- ○ Low
R&D spending is 11925% of revenue — heavy investment in future growth, but also a drag on current profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade PRGO
Links open broker research pages. Not an endorsement or recommendation.
Research Perrigo Company plc
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.